{{Chembox new
|ImageFile=R207910.svg
|ImageSize=250px
|IUPACName=(1R,2R)-1-(6-bromo-2-methoxyquinolin-3-yl)- 4-(dimethylamino)-2-
(3-fluorophenyl)-1-phenylbutan-2-ol
|OtherNames=AIDS222089
|Section1= {{Chembox Identifiers
|  CASNo=654653-81-3
|  PubChem=5746640
|  SMILES=
|  MeSHName=R207910
  }}
|Section2= {{Chembox Properties
|  Formula=C<sub>28</sub>H<sub>28</sub>BrFN<sub>2</sub>O<sub>2</sub>
|  MolarMass=523.437 g/mol
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3= {{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}
'''R207910''' (also known as TMC207) is an experimental diarylquinoline anti-ICAAC) meeting Late-Breaker Session, after the drug had been in development for over 7 years<ref>[http://www.sequella.com/docs/TB_Drugs_Review.pdf In Search of New Cures for Tuberculosis]</ref>.

==Mode Of Action==
R207910 affects the proton pump for ATP synthase, which is unlike other quinolones, whose target is DNA gyrase.<ref>[http://www.nature.com/nchembio/journal/vaop/nprelaunch/full/nchembio002.html Joanne Kotz, Targeting tuberculosis, Nature Chemical Biology, Published online: 8 February 2005] (doi: 10.1038/nchembio002)</ref>

==References==

{{ChemischeStof|
| Naam = 
| Afb1 = 200px
| Afb1Omschr = Structuur van R207910
| Afb2 = 
| Afb2Omschr = 
| Afb3 = 
| Afb3Omschr = 
| Afb4 = 
| Afb4Omschr = 
| Formule = C<sub>28</sub>H<sub>28</sub>BrFN<sub>2</sub>O<sub>2</sub>
| Molgewicht = 523,436523 
| SMILES = CN(C)CC[C@@](C1=CC(=CC=C1)F)([C@H](C2=CC=CC=C2)C3=C(N=C4C=CC(=CC4=C3)Br)OC)O
| InChI = InChI=1/C28H28BrFN2O2/c1-32(2)15-14-28(33,21-10-7-11-23(30)18-21)26(19-8-5-4-6-9-19)24-17-20-16-22(29)12-13-25(20)31-27(24)34-3/h4-13,16-18,26,33H,14-15H2,1-3H3/t26-,28-/m1/s1
| IUPAC = (1R,2S)-1-(6-broom-2-methoxychinolin-3-yl)-4-dimethylamino-2-(3-fluorfenyl)-1-fenylbutan-2-ol
| AndereNamen = 
| CAS = 654653-81-3
| EINECS =
| PubChem = 5746640
| Beschrijving = 
| Vergelijkbaar = 
| AfbWaarsch = 
| TekstWaarsch = 
| Carcinogeen = 
| Hygroscopisch = 
| Rzinnen = 
| Szinnen = 
| Omgang = 
| Opslag = 
| EG = 
| VN = 
| ADR = 
| MAC = 
| LethaalRat = 
| LethaalKonijn = 
| LethaalMuis =
| MSDS = 
| Aggregatie = 
| Kleur = 
| Dichtheid = 
| Smeltpunt = 
| Kookpunt = 
| Vlampunt = 
| Zelfontbranding = 
| Dampdruk = 
| Oplosbaarheid = 
| GoedOplIn = 
| MatigOplIn =
| SlechtOplIn = 
| OnoplIn = 
| LogPow =
| Viscositeit = 
| Brekingsindex =
| Kristalstructuur = 
| Dipoolmoment = 
| fG0g = 
| fG0l = 
| fG0s = 
| fH0g = 
| fH0l = 
| fH0s = 
| S0g = 
| S0l = 
| S0s = 
| Cpm0 = 
| Evenwicht = 
| KlassiekeAnalyse = 
| Spectra =

}}

'''R207910''' (ook bekend als '''TMC207''') is een experimenteel medicijn tegen tuberculose, behorend tot de familie van de '''diarylchinolines''' dat momenteel (2005) nog in ontwikkeling is.<ref>Andries K, Verhasselt P, Guillemont J, et al. (2005), A diarylquinoline drug active on the ATP-synthase of Mycobacterium tuberculosis, Science 307 (5707): 223–27</ref>  
Het is circa 40 jaar geleden dat er voor het laatst een nieuw anti-TBC middel is ontwikkeld. Het werkingsmechanisme is geheel anders dan van de bestaande tuberculostatica: het remt resistentie tegen dit middel zal gaan ontstaan.